filmov
tv
PD-1 Inhibitor/DNA Vaccine Combination Trial in GBM
Показать описание
0:08:10
PD-1 Inhibitor/DNA Vaccine Combination Trial in GBM
0:01:24
GBM: Rationale for Combining PD-1 Inhibitor/DNA Vaccine
0:23:02
Immunotherapy: Moving beyond PD1 and PDL1 inhibitors
0:03:48
AHEAD-MERIT: first-line pembrolizumab and BNT113 in advanced HPV16+ HNSCC
0:36:47
Next Generation Oncolytic Immunotherapy
0:03:13
Promise of DNA Vaccines in Bladder Cancer
0:40:23
James P. Allison, Ph.D., on Targeting Immune Checkpoints in Cancer Therapy
0:01:05
Combining a DNA vaccine with pembrolizumab for mCRPC
0:03:43
TESLA: TG01/QS-21 ± PD-1 inhibitor for MRD in RAS mutated pancreatic cancer
0:57:18
Webinar - PD-1/PD-L1 Inhibitors: The First Wave of Immuno-Oncology
0:45:18
James Allison, PhD - Immune Checkpoint Blockade in Cancer Therapy (2020)
0:45:55
Immuno-Oncology Biomarker Update and Testing Challenges
0:50:26
PD-1/PD-L1 Inhibitors: The First Major Wave of Immuno-Oncology | informa Tokyo seminar
0:01:06
Dr. Necchi on Impact of PD-1 Inhibition in Bladder Cancer
0:37:31
Update on Immuno-Oncology Biomarkers
0:44:25
Using HDAC Inhibitors to Improve Cancer Immunotherapy
0:17:15
Is immunomodulation really needed to cure HBV? | Harry Janssen, MD, PhD
0:30:54
Cellular Therapies Symposium 2015 (Part 2) | UCLA Children's Discovery and Innovation Institute
0:39:06
Expanding the Benefits of Immuno-Oncology Through Novel Rational Targets and Combinations
0:01:38
Dr. Usmani on PD-1/PD-L1 Inhibitors in Hematologic Malignancies
0:30:02
Imugene's Science Series featuring the Oncolytic Viraltherapy CHECKvacc
0:48:15
Immunotherapy for Lung Cancer: PD-1 and Beyond, with Naiyer Rizvi
0:01:40
Pros and cons of immune checkpoint inhibitors for tumor immunotherapy
0:50:35
Dr. Deb Fuller - Vaccine Development 101
Комментарии